Back to Browse Journals » Core Evidence » Volume 6

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma

Authors Brian Poligone, Janet Lin, Catherine Chung

Published Date December 2010 Volume 2011:6 Pages 1—12


Published 22 December 2010

Brian Poligone, Janet Lin, Catherine Chung
Wilmot Cancer Center, Department of Dermatology, University of Rochester School of Medicine, Rochester, NY, USA

Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and Sézary syndrome.
Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL.
Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia.
Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.

Keywords: cutaneous T cell lymphoma, mycosis fungoides, Sézary syndrome, romidepsin, histone deacetylase inhibitor, treatment

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Molino CGRC, Carnevale RC, Rodrigues AT, Visacri MB, Moriel P, Mazzola PG

Therapeutics and Clinical Risk Management 2014, 10:631-639

Published Date: 7 August 2014

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma

Babu R, Adamson DC

Core Evidence 2012, 7:93-103

Published Date: 14 September 2012


Todd Levine

Drug Design, Development and Therapy 2012, 6:163-164

Published Date: 21 June 2012

Perfluorocarbon-perfused 23 gauge three-dimensional vitrectomy for complicated diabetic tractional retinal detachment

Velez-Montoya R, Guerrero-Naranjo JL, Garcia-Aguirre G, Morales-Cantón V, Fromow-Guerra J, Quiroz-Mercado H

Clinical Ophthalmology 2011, 5:1709-1715

Published Date: 20 December 2011

Multiple treatment comparison meta-analyses: a step forward into complexity

Mills E, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, Wright J

Clinical Epidemiology 2011, 3:193-202

Published Date: 27 May 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011